Patient diversity remains a problem in clinical trials. Although FDA-approved medicines serve a diverse population of Americans, participation in clinical trials remains predominantly white and male. There is a lot that still needs to be done to increase the enrollment of minority populations in clinical trials.
In this webinar segment, RADM Richardae Araojo, associate commissioner for minority health and director of the Office of Minority Health and Health Equity, discusses community engagement and why it is critical to patient recruitment. Community engagement helps sponsor companies overcome barriers that exist and raises awareness of trials in non-white communities. Araojo also discusses some successful strategies companies have used to increase patient diversity in their trials.